The FirstTake Podcast – NK Cell therapy, CAR-T in solid tumours and our early take on Q1 earnings season

The FirstTake Podcast – Previewing AACR

The FirstTake Podcast – The FDA faces up to a tricky ALS regulatory decision, Roche’s TIGIT setback and more…

The FirstTake Podcast – A landmark cancer approval, Pfizer’s Arena deal delivers and the expert view on recent breast cancer developments

The FirstTake Podcast – Sanofi’s breast cancer hopeful fails to deliver

The FirstTake Podcast – Gilead’s oncology strategy under the spotlight

The FirstTake Podcast – Where next for gene editing?

The FirstTake Podcast – Does a paradigm shift in breast cancer beckon?

The FirstTake Podcast – More questions than answers for Sage and Biogen

The FirstTake Podcast – AdCom upset for Lilly and Innovent

The FirstTake Podcast – More Aduhelm fallout and JP Morgan wraps for another year

The FirstTake Podcast – Previewing next week’s JP Morgan healthcare conference

The FirstTake Podcast – Does 2022 promise a bumper year in pharma M&A?

The FirstTake Podcast – Three doses are better than two

The First Take – Pharma's pandemic takes a new twist

The First Take – Pfizer’s antiviral haul, BMS lays out a growth strategy and Biogen’s week to forget

The First Take – Pfizer makes migraine move

The First Take – Novartis sells Roche stake for big bucks

The First Take – Q3 earnings season kicks into gear

The First Take – Biogen banks on Medicare decision to rescue Aduhelm